Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Shiying He
Advertisement
Shiying He is a senior consultant for Simon-Kucher.
Articles by Shiying He
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Rebuilding Clinical Data Workflows for the AI Era
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5